Scarica l'app Stockscreener
2.39
0.83%
-0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$2.41
Aprire:
$2.38
Volume 24 ore:
13,440
Relative Volume:
0.48
Capitalizzazione di mercato:
$72.87M
Reddito:
$300.00K
Utile/perdita netta:
$-40.16M
Rapporto P/E:
-1.8142
EPS:
-1.3174
Flusso di cassa netto:
$-42.36M
1 W Prestazione:
+3.91%
1M Prestazione:
+0.84%
6M Prestazione:
-4.78%
1 anno Prestazione:
-21.64%
Intervallo 1D:
$2.35
$2.40
Intervallo di 1 settimana:
$2.30
$2.4352
Portata 52W:
$2.09
$3.61
Xbiotech Inc Stock (XBIT) Company Profile
Nome
Xbiotech Inc
Settore
Industria
Telefono
512-386-2900
Indirizzo
5217 WINNEBAGO LANE, AUSTIN, TX
Compare XBIT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XBIT
Xbiotech Inc
|
2.39 | 73.48M | 300.00K | -40.16M | -42.36M | -1.3174 |
VRTX
Vertex Pharmaceuticals Inc
|
524.65 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.72 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.14 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.74 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.41 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xbiotech Inc Stock (XBIT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-06-14 | Iniziato | Piper Jaffray | Overweight |
| 2017-04-21 | Downgrade | Noble Financial | Buy → Hold |
| 2016-06-28 | Reiterato | Noble Financial | Buy |
Xbiotech Inc Borsa (XBIT) Ultime notizie
ETFs Investing in XBiotech, Inc. Stocks - TradingView
XBiotech, Inc. Actuals & Estimates (SWB:4XB) - TradingView
XBiotech, Inc. Actuals & Estimates (LS:A14QF1) - TradingView
XBiotech, Inc. Actuals & Estimates (FWB:4XB) - TradingView
Price to earnings forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (MUN:4XB) - TradingView
XBiotech, Inc. Actuals & Estimates (NASDAQ:XBIT) - TradingView
Price to sales forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (BX:4XB) - TradingView
Enterprise value to revenue forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (BOATS:XBIT) - TradingView
Price to book forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech Inc (XBIT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
XBiotech to commence V-SPINE trial enrolment for vilamakitug - MSN
XBiotech Inc (XBIT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
XBiotech Inc (XBIT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XBiotech Inc (XBIT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
XBiotech Inc (XBIT) Valuation: PE, PB & Fair Value Analysis - TradingKey
XBiotech Inc (XBIT) Institutional Confidence - TradingKey
XBiotech Inc (XBIT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XBiotech Inc (XBIT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
XBiotech Inc (XBIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XBIT Earnings Overview 2026-06-16Profit Warning Alert - dars.gov.et
XBiotech Receives Authorization for V-SPINE Trial - Intellectia AI
XBiotech Inc Stock (US9840001002): FDA clears Phase II V-SPINE trial for vilamakitug in axial spondy - AD HOC NEWS
XBiotech (XBIT) Receives FDA Nod for V-SPINE Study - GuruFocus
XBiotech clears FDA review for axial spondyloarthritis study - Investing.com
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis - Yahoo Finance UK
XBiotech Inc. (XBIT) Holds Near Support Amidst Minor DeclinesDescending Triangle - newsline.com
XBIT Should I Buy - Intellectia AI
XBiotech Inc stock (US9840001002): shares little changed as investors await next earnings update - Ad-hoc-news.de
XBiotech Inc. (XBIT) Slips 2.27% as Stock Tests Key Support LevelsMotive Wave - The Legal Advocate
XBITXBiotech Inc Dividends - Finviz
XBiotech Inc. (XBIT) Edges Higher, Approaching Key Resistance at $2.56Trading Ideas - The Legal Advocate
XBiotech Inc. (XBIT) Edges Higher on Modest Volume, Tests Resistance Near $2.58Composite Profile - The Legal Advocate
XBIT | XBiotech Inc Insider Trading - Quiver Quantitative
XBiotech stock (US9840001002): Clinical-stage biotech stays in focus - AD HOC NEWS
XBiotech: Q1 Earnings Snapshot - Stamford Advocate
XBiotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
XBiotech (NASDAQ: XBIT) trims Q1 2026 loss, holds $115.5M cash and cuts R&D spend - Stock Titan
XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ Radar - TipRanks
TradingKey - TradingKey
Number of shareholders of XBiotech, Inc. – FWB:4XB - TradingView
XBiotech (XBIT) Projected to Post Earnings on Tuesday - MarketBeat
XBIT (XBiotech) reports zero Q1 2020 EPS missing estimates, shares dip 0.78 percent amid investor concern.Post Announcement - newser.com
XBiotech Inc. 2025 Executive Compensation, Board Structure, and Shareholder Ownership Overview - Minichart
Executive pay and governance detailed in XBiotech (NASDAQ: XBIT) 10-K/A - Stock Titan
XBIT Stock: A Comprehensive Guide to XBiotech Inc. - Bitget
XBIT (XBiotech) posts 100 percent Q1 2020 EPS miss, falls 0.79 percent on soft investor sentiment.Trader Community Insights - newser.com
XBIT (XBiotech Inc.) reports 100 percent Q1 2020 EPS miss, while shares notch mild gains on upbeat investor sentiment.Dividend Cut Risk - Xã Thanh Hà
XBiotech (XBIT) Stock: Price Action Overview (Smart Money Active) 2026-04-18Verified Analyst Reports - Xã Vĩnh Công
Xbiotech Inc Azioni (XBIT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.47%
2.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):